According to a statement which was came out in a regulatory filing by Natco Pharma, "Our marketing partner named BPI (Breckenridge Pharmaceutical Inc) has got the final approval for its ANDA, which stands for Abbreviated New Drug Application for everolimus tablets (a generic version of Afinitor) from the US Food and Drug Administration (USFDA). Natco's partner Breckenridge Pharmaceutical Inc (BPI) aims to launch 7.5 mg, 5 mg, and 2.5 mg strengths of the xeverolimus tablets presently within the upcoming few weeks. According to Natco Pharma, "The launching of everolimus as the strength of 10 mg is completely subject to the confidential terms of a settlement and licence agreement entered into with the owner of the brand Afinitor." "The launch date of everolimus as the strength of 10 mg will be declared after a certain period of time,'' the company added. The above mentioned strengths of Everolimus are indicated in order to treat breast cancer and certain other types of cancers. On behalf of industry sales data, Natco Pharma stated Afinitor and its therapeutic equivalents had given rise to annual sales of about 712 million USD in the United State of America during the 12 months ending December 2020. Natco Pharma's shares were trading 6.45 % higher at Rs 886.50 apiece on the BSE. Reference: https://www.financialexpress.com/lifestyle/health/natcos-marketing-partner-gets-usfda-nod-for-cancer-treatment-drug/2208320/
0 Comments
Leave a Reply. |
AuthorMy Name is Amit Sharma I am a pharmacist, I am having 25+ years of experience in Pharma medications. ArchivesCategories
All
|